About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Memory Deterioration in Alzheimer Disease

NCT07118137·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Axel Sandvig Professor, MD & PhD
CONTACT
+4745840578 axel.sandvig@ntnu.no
Varanann Varathalingam
CONTACT
varananv@ntnu.no

Lead

Norwegian University of Science and Technology

Age

55–any

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Confirmed diagnosis based on current ICD criteria for AD or MCI .
\>55years.
Norwegian native speaker
Lives at home and not in a health institution

You may not be if

Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2).
Presence of brain tumors.
History of traumatic brain injury.
History of cranial surgery.
Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG).
Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.
7T MRI contraindications:
Large tattoos close to the head region, permanent makeup or unremoveable piercings
Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred)
Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)

The record

StatusRecruiting

PhaseNo phase

Taking part30

StartedOct 2023

UpdatedAug 13, 2026

Conditions

Alzheimer Disease Neurodegenerative Diseases Magnetic Resonance Imaging Memory Impairment

Where1

Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)
Trondheim, Trønderlag, Norway